Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013
Purser M, Mladsi DM, Kaye JA. Cost-effectiveness of sonidegib versus vismodegib for the treatment of patients with locally advanced basal cell carcinoma not amenable to surgery or radiotherapy. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A731.
Hoffman E, Mladsi DM, Cryer B, Hopkins W, Brater DC, Parikh R, Goyal R, Castellsague J, Stafkey-Mailey D, Young C. Dose-related risks of cardiovascular, gastrointestinal, and renal adverse events associated with meloxicam among patients with osteoarthritis: an observational study using US claims data. Poster presented at the 2016 ACR/ARHP Annual Meeting; November 15, 2016. Washington, DC. [abstract] Arthritis Rheumatol. 2016 Sep 28; 68(Suppl 10).
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Prefer Adherence. 2016 Jun 8;2016(10):1025-35. doi: 10.2147/PPA.S102760
Odom D, Mladsi DM, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A122.
Herring W, Mladsi DM. External validation of health economic models for complex chronic diseases: lessons from a population model for diabetic retinopathy. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A88.
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States. Patient Prefer Adherence. 2016 Jan 21;10:45-55. doi: 10.2147/PPA.S93320.
Boklage SH, Mangel AW, Ramamohan V, Mladsi DM, Wang T. Effects of patient compliance on the cost-effectiveness of non-invasive tests for initial diagnosis of H. pylori infection in a high prevalence population. Poster presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology; October 17, 2014. Philadelphia, PA.
Boklage S, Mangel AW, Ramamohan V, Mladsi DW, Wang T. Cost-effectiveness of noninvasive active tests for universal post-treatment confirmation of eradication of H. pylori infection. Poster presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology; October 2014. Philadelphia, PA.
Purser MF, Mladsi DM, Wolowacz SE. A review of NICE technology appraisals using single-arm trials. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014. Montreal, Canada.
Odom DM, Mladsi DM, Saag KG, Sherif BN, Miles L, Ronquest N, Wang J. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014 Jun;36(6):906-17. doi: 10.1016/j.clinthera.2014.04.012.
Ramamohan V, Mladsi DM, Kaye JA, Boey W, Pozzi R. An outcomes model for high-risk non-muscle-invasive bladder cancer treatment options. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A87.
Purser MF, Wilson MR, Mladsi DM, Wu Y. Literature review of economic models for the treatment of parkinson's disease. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A60. doi: 10.1016/j.jval.2014.03.355
Mladsi DM, Redekop K, Goettsch A, Earnshaw SR. Challenges and insights in establishing and communicating the economic value of companion diagnostics. Presented at the 2010 ISPOR 13th Annual European Congress; November 2010. Prague, Czech Republic.
Mladsi D. Review of utility estimates in atopic dermatitis. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A402.
Mladsi D, Earnshaw S, Ronquest NA, Keith M. The threshold pricing model: not just another cost-effectiveness model. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A332.
Mladsi D, Earnshaw S, Akashi-Ronquest N, Keith M. Proposed methods for conducting sensitivity analyses on threshold-derived estimates of value-based price and product profiles of early stage drugs. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A333.
French M, Neighbors D. A model to estimate the compliance costs of food labeling regulations. In: J.A. Caswell, editors. The economics of food safety. New York: United States. New York: Elsevier Science Publishing Co, Inc; 1991. p.299-325.